Within the diabetes associated ophthalmic treatment market, Drugs held a 60.38% share in 2025, reflecting their central role in managing diabetic eye complications through established treatment pathways. This leadership is maintained through routine clinical use, broad physician familiarity, and the practicality of drug-based intervention across a wide range of disease severities before more procedure-oriented options are required. The segment’s position is also reinforced by the fact that pharmacological treatment often serves as a first-line or recurring component of care, supporting continued demand across hospital and specialty ophthalmic settings.

Devices are emerging as the fastest-growing segment in the diabetes associated ophthalmic treatment market as care delivery increasingly shifts toward precision-led diagnosis, monitoring, and intervention. Their momentum is being encouraged by the growing need for more targeted and procedure-based management of diabetic ophthalmic conditions, particularly where visual preservation depends on timely and controlled treatment. Compared with drugs, devices gain traction when clinicians require greater procedural accuracy or when disease progression calls for intervention beyond pharmacological management, making them the faster-rising option in evolving treatment workflows.

End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Centres (Fastest-Growing Segment)

Hospitals accounted for the largest share of the diabetes associated ophthalmic treatment market in 2025, supported by their ability to manage complex diabetic eye conditions within integrated care environments. Their leadership is anchored in access to multidisciplinary specialists, advanced diagnostic infrastructure, and the capacity to deliver both medical and procedural treatment under one setting. This makes hospitals the preferred end-use segment for patients requiring coordinated diabetes and ophthalmic care, especially when complications demand closer monitoring or escalation of treatment.

Ambulatory Centres represent the fastest-growing end-use segment in the diabetes associated ophthalmic treatment market as providers and patients increasingly favor efficient outpatient care models. Growth is being supported by the practical shift toward shorter-visit treatment pathways for suitable ophthalmic procedures and follow-up care, where ambulatory settings can offer faster scheduling and more streamlined service delivery than hospitals. Their expansion relative to other end-use settings reflects the rising importance of accessible, lower-burden care for recurring diabetes-related eye management.